S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

Trevena Stock Price, Forecast & Analysis (NASDAQ:TRVN)

$0.70
+0.07 (+11.11 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$0.64
Now: $0.70
$0.73
50-Day Range
$0.63
MA: $0.89
$1.03
52-Week Range
$0.38
Now: $0.70
$2.00
Volume895,500 shs
Average Volume1.58 million shs
Market Capitalization$64.82 million
P/E RatioN/A
Dividend YieldN/A
Beta2.63
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TRVN
CUSIPN/A
Phone610-354-8840

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.73 million
Book Value$0.37 per share

Profitability

Net Income$-30,780,000.00

Miscellaneous

Employees29
Market Cap$64.82 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive TRVN News and Ratings via Email

Sign-up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.


Trevena (NASDAQ:TRVN) Frequently Asked Questions

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

How were Trevena's earnings last quarter?

Trevena Inc (NASDAQ:TRVN) released its quarterly earnings data on Monday, November, 4th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.02. View Trevena's Earnings History.

When is Trevena's next earnings date?

Trevena is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Trevena.

What price target have analysts set for TRVN?

1 Wall Street analysts have issued 12-month price objectives for Trevena's shares. Their forecasts range from $3.50 to $3.50. On average, they expect Trevena's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price. View Analyst Price Targets for Trevena.

What is the consensus analysts' recommendation for Trevena?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevena.

What are Wall Street analysts saying about Trevena stock?

Here are some recent quotes from research analysts about Trevena stock:
  • 1. According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (11/16/2019)
  • 2. HC Wainwright analysts commented, "Our $3.50 price target for Trevena is based on our sum-of-the-parts NPV valuation based on each of the company’s pipeline assets. Our DCF model utilizes a discount rate of 11.5% based on the company’s WACC (Beta of 1.5, equity risk premium of 6.7%). We adjust each indication for probability of success with 3 program has been successful, and we’re confident on the outcome of the cardiac safety study; TRV-250 at 15%; and TRV-045 at 7%. We don’t include TRV-734 in our valuation for the time being, although would look to add it to our valuation model as we gain additional insight. We apply terminal decline rates of 10% for each asset. We assume a 24% tax rate." (5/31/2019)

Has Trevena been receiving favorable news coverage?

Press coverage about TRVN stock has trended somewhat negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Trevena earned a news sentiment score of -1.9 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Trevena.

Are investors shorting Trevena?

Trevena saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 6,050,000 shares, a drop of 6.1% from the September 30th total of 6,440,000 shares. Based on an average daily trading volume, of 527,100 shares, the days-to-cover ratio is currently 11.5 days. Approximately 7.4% of the shares of the company are short sold. View Trevena's Current Options Chain.

Who are some of Trevena's key competitors?

What other stocks do shareholders of Trevena own?

Who are Trevena's key executives?

Trevena's management team includes the folowing people:
  • Ms. Carrie L. Bourdow, Pres, CEO & Director (Age 56)
  • Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Mr. John P. Hamill, VP of Fin. (Age 55)
  • Erin Clark, Sr. Director of Corp. Strategy & Investor Relations
  • Mr. Michael Catalano, VP of Marketing

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $0.70.

How big of a company is Trevena?

Trevena has a market capitalization of $64.82 million and generates $5.73 million in revenue each year. The biopharmaceutical company earns $-30,780,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Trevena employs 29 workers across the globe.View Additional Information About Trevena.

What is Trevena's official website?

The official website for Trevena is http://www.trevena.com/.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]


MarketBeat Community Rating for Trevena (NASDAQ TRVN)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  544 (Vote Outperform)
Underperform Votes:  242 (Vote Underperform)
Total Votes:  786
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel